IGF-II/IGF2 Antibody (DX-2647) [Allophycocyanin]
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-27979APC
Recombinant Monoclonal Antibody
Conjugate
Catalog #
Key Product Details
Species Reactivity
Validated:
Human
Applications
ELISA, Flow Cytometry, Functional
Label
Allophycocyanin (Excitation = 620-650 nm, Emission = 660-670 nm)
Antibody Source
Recombinant Monoclonal Human IgG1 Clone # DX-2647
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Summary for IGF-II/IGF2 Antibody (DX-2647) [Allophycocyanin]
Immunogen
IGF-2
Clonality
Monoclonal
Host
Human
Isotype
IgG1
Applications for IGF-II/IGF2 Antibody (DX-2647) [Allophycocyanin]
Application
Recommended Usage
ELISA
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Functional
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
PBS
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: IGF-II/IGF2
Long Name
Insulin-like Growth Factor II
Alternate Names
C11orf43, GRDF, IGF-2, IGF2, IGFII, MSA, PEG2, PP9974
Gene Symbol
IGF2
Additional IGF-II/IGF2 Products
Product Documents for IGF-II/IGF2 Antibody (DX-2647) [Allophycocyanin]
Product Specific Notices for IGF-II/IGF2 Antibody (DX-2647) [Allophycocyanin]
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...